Core structure of gp41 from the HIV envelope glycoprotein
- PMID: 9108481
- DOI: 10.1016/s0092-8674(00)80205-6
Core structure of gp41 from the HIV envelope glycoprotein
Abstract
The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) consists of a complex of gp120 and gp41. gp120 determines viral tropism by binding to target-cell receptors, while gp41 mediates fusion between viral and cellular membranes. Previous studies identified an alpha-helical domain within gp41 composed of a trimer of two interacting peptides. The crystal structure of this complex, composed of the peptides N36 and C34, is a six-helical bundle. Three N36 helices form an interior, parallel coiled-coil trimer, while three C34 helices pack in an oblique, antiparallel manner into highly conserved, hydrophobic grooves on the surface of this trimer. This structure shows striking similarity to the low-pH-induced conformation of influenza hemagglutinin and likely represents the core of fusion-active gp41. Avenues for the design/discovery of small-molecule inhibitors of HIV infection are directly suggested by this structure.
Similar articles
-
Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9134-9. doi: 10.1073/pnas.95.16.9134. Proc Natl Acad Sci U S A. 1998. PMID: 9689046 Free PMC article.
-
Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.Biochemistry. 2000 Feb 22;39(7):1634-42. doi: 10.1021/bi9921687. Biochemistry. 2000. PMID: 10677212
-
Atomic structure of a thermostable subdomain of HIV-1 gp41.Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12303-8. doi: 10.1073/pnas.94.23.12303. Proc Natl Acad Sci U S A. 1997. PMID: 9356444 Free PMC article.
-
Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.Eur J Med Chem. 2011 Apr;46(4):979-92. doi: 10.1016/j.ejmech.2011.01.046. Epub 2011 Feb 3. Eur J Med Chem. 2011. PMID: 21345545 Review.
-
Multimerized HIV-gp41-derived peptides as fusion inhibitors and vaccines.Biopolymers. 2016 Nov 4;106(4):622-8. doi: 10.1002/bip.22782. Biopolymers. 2016. PMID: 26583370 Review.
Cited by
-
HIV-1 entry inhibitors: recent development and clinical use.Curr Opin Virol. 2013 Feb;3(1):51-7. doi: 10.1016/j.coviro.2012.12.002. Epub 2013 Jan 3. Curr Opin Virol. 2013. PMID: 23290628 Free PMC article. Review.
-
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278. Cold Spring Harb Perspect Med. 2011. PMID: 22229123 Free PMC article. Review.
-
Protease-resistant peptide design-empowering nature's fragile warriors against HIV.Biopolymers. 2012;98(5):431-42. doi: 10.1002/bip.22073. Biopolymers. 2012. PMID: 23203688 Free PMC article. Review.
-
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Viruses. 2012 Dec;4(12):3859-911. doi: 10.3390/v4123859. Viruses. 2012. PMID: 23342377 Free PMC article. Review.
-
Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology.Pharmaceuticals (Basel). 2024 Jul 4;17(7):887. doi: 10.3390/ph17070887. Pharmaceuticals (Basel). 2024. PMID: 39065738 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
